Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat and SOCS box-containing protein 1 (WSB1) is a substrate recognition protein within an E3 ubiquitin ligase complex. It contains multiple WD40 domains at the N-terminus and a SOCS box at the C-terminus. WSB1 is involved in targeted protein ubiquitination and degradation, affecting key proteins involved in cell cycle, hypoxia response, glucose metabolism, immune regulation, and neuroprotection. It is transcriptionally regulated in response to hypoxia via HIF-1 and has been implicated as a regulator of cancer cell proliferation and metastasis through degradation of tumor suppressor proteins (e.g., VHL, ATM). WSB1 also affects thyroid hormone activation through modulation of deiodinase D2. Dysregulation of WSB1 has been linked to poor prognosis in cancers and may modulate cellular responses relevant to neurodegeneration and metabolic disease.
Drugs targeting WSB1 would likely act by modulating its substrate recognition or E3 ligase activity (ubiquitin-proteasome system regulation), affecting degradation of proteins such as ATM, VHL, HIPK2, RhoGDI2, and others
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD repeat and SOCS box-containing protein 1 (WSB1).